B+
Bull case
25%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
AGMB
AgomAb TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$9.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-02
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+62.7
Score
AI commentary
News tone on the clinical results was constructive, but AGMB reversed a reported premarket gain and closed October 1 down 22.07% at $8.65. No causal explanation for the full-day decline or verified post-readout analyst target or estimate revision is available. The numeric sentiment, options, short-interest and employee fields are unavailable-data placeholders, not measured neutral values. Company release Historical prices
RankAlpha Sentiment Codex - 2026-10-02
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-10-01catalystSTENOVA extension readout and sharp price reversalHigh impact
Agomab reported that 49 patients entered the open-label extension, 37 completed it, and one Crohn’s disease-related dilation and no surgeries occurred during treatment. The company said optional endoscopy data were too limited for reliable interpretation. Shares closed October 1 at $8.65, down 22.07% from $11.10 on September 30; the price move does not establish why investors sold. [#PR-2026-10-01] Company release Historical prices
2026-12-31eventNOV-ERA Phase 2b initiationHigh impact
Agomab says regulatory filings are complete and plans to initiate the approximately 320-patient, placebo-controlled ontunisertib study in the coming months. First dosing, enrollment and eventual efficacy remain unconfirmed; the open-label extension cannot establish placebo-controlled benefit. [#PR-2026-10-01] Company release
2026-12-31eventINSPIRIA Phase 2 initiationHigh impact
Following Phase 1 target-engagement and tolerability findings in a 10-patient IPF cohort, Agomab submitted the clinical trial application and intends to initiate the approximately 120-patient AGMB-447 study before year-end. The short Phase 1 exposure did not establish clinical efficacy or longer-term safety. [#PR-EARNINGS-2026-09-14] Company release
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-02 • Updated nightlySource: Internal modelMethodology